ProKidney Corp. (PROK), a pioneer in the treatment of chronic kidney disease, is set to present full results from its Phase 2 REGEN-007 trial as a late-breaking clinical presentation at the American Society of Nephrology (ASN) 2025 Kidney Week, taking place from November 5 to 9, 2025, in Houston, Texas.
The data will spotlight the company's lead autologous cell therapy candidate, rilparencel, in patients with chronic kidney disease (CKD) and type 2 diabetes.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com